| (Values in U.S. Thousands) | Oct, 2021 | Oct, 2020 | Oct, 2019 | Oct, 2018 | Oct, 2017 |
| Sales | 3,240 | 250 | 20,880 | 6,060 | 12,030 |
| Sales Growth | +1,196.00% | -98.80% | +244.55% | -49.63% | +201.50% |
| Net Income | -17,860 | -26,470 | -16,610 | -66,520 | -93,440 |
| Net Income Growth | +32.53% | -59.36% | +75.03% | +28.81% | -27.03% |
Advaxis Inc
(ADXSD)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P.